The present study was undertaken to evaluate the prevalence of predominant bacterial mpathogens among clinical samples and their drug sensitivity and resistance profiles. The study was done from January 2014 to December, 2014 in the Department of Microbiology, Venus Medicine Research Centre, Baddi, Himachal Pradesh. A total of 1385 clinical samples were collected and subjected for identification of pathogens. The antibiotic sensitivity testing was performed by cup plate method.
Out of 1385 samples, 679 samples showed the growth of bacteria. Further identification revealed the presence of five different Gram-negative organisms with high prevalence of Pseudomonas aeruginosa (45.2%), followed by Aceinetobacter baumannii (33.6%), E. coli (15.0%), Klebsiella species (5.9%) and Proteus species (0.3%). The susceptibility of Tobracef against P. aeruginosa, A. baumannii, E. coli, Klebsiella spp. and Proteus spp. was 88.9, 89.0, 89.2, 77.5 and 100 %, respectively which was high compared to ceftazidime, tobramycin, amikacin, gentamicin and ceftazidime plus amikacin. A high resistance to ceftazidime (49.8 to 57.8%), tobramycin (25.5 to 75%), amikacin (27.5 to 100%), gentamicin (50 to 100%) and ceftazidime plus amikacin (15.7 to 50 5) was observed against all the isolates. The results of the present study advocates the superiority of Tobracef over other tested antibiotics for the treatement of infections caused by Gram negative bacteria.
